Kornimate/medical-research-clean huggingface dataset:
circumcision versus preputioplasty for bxo in children

Conditions: Balanitis Xerotica Obliterans (BXO)

Summary: traditionally, bxo is managed with circumcision (surgical removal of the foreskin) and this approach has long been held as the 'gold standard. whilst this may be curative in many cases, it has been shown that 20% of boys require a further operative procedure on their penis to widen the urethral opening (to treat meatal stenosis) an alternative to circumcision was proposed: a preputioplasty (surgery to widen the opening of the foreskin) was combined with injection of steroids into the affected foreskin. subsequently, the same group compared the outcomes of this technique with circumcision, and reported circumcision was successfully avoided in 92% of the preputioplasty group. in addition, the rate of meatal stenosis (narrowing of the urethral opening requiring surgery) was significantly lower (6% vs 19%, p = .034 ). preputioplasty may therefore: (i) offer protection against meatal stenosis and reduce the requirement for further surgery; and (ii) offer the benefit of retaining the foreskin, the function of which, while debated, likely includes sexual function. in view of these potential benefits, authors have called for a randomised trial to compare circumcision to preputioplasty and injection of steroids.

the interventions to be compared are operations to treat bxo called: (i) circumcision: this will be a standard surgical circumcision whereby the prepuce (foreskin of the penis) is excised and the cut edge of the outer prepuce sutured to the cut edge of the inner prepuce. the two study team members performing the surgery in this trial (hc and sk) will be free to choose the method of circumcision (e.g. guillotine vs. sleeve) as this is not thought to influence outcome. the foreskin will be sent for histological analysis. (ii) preputioplasty with intralesional injection of triamcinolone. briefly, longitudinal incisions will be placed in the area of phimosis, and these will be sutured transversely to allow the prepuce to become retractile. a biopsy of an area of affected foreskin will be sent for histological analysis. the intention will be to perform three incisions (tri-radiate) but the final decision on how many will be made by the operating surgeon and based on the appearance of the prepuce and result of initial incision(s). once the prepuce is felt to be freely retractile, 1 - 3 ml of triamcinolone (adcortyl bristol-myers squibb 10 mg/ml) will be injected intradermally around the circumference of the affected foreskin using a 25-gauge needle. these procedures are established treatments for bxo and currently in use by the trial surgeons in the same setting as the trial.the preputioplasty with injection of triamcinolone procedure has previously been approved by the alder hey children's hospital nhs trust clinical development evaluation group (cdeg).

Eligibility criteria:
inclusion criteria: * aged between 2 and 16 years * diagnosed with bxo * require surgery to treat bxo exclusion criteria: * previous penile surgery * circumcision or preputioplasty medically contraindicated
pectoral nerves blocks for chronic pain

Conditions: Breast Neoplasms

Summary: the purpose of this study is to determine whether pectoral nerves blocks（pecs） would reduce chronic pain at 3 months after modified radical mastectomy（mrm）surgery.

one hundred and forty adult female participants scheduled for elective unilateral modified radical mastectomy under general anesthesia are randomly allocated to receive either general anesthesia plus pecs block(pecs group, n=70) or general anesthesia alone (control group, n=70). after arrived in the operating room，the participants in the control group are accepted the general anesthesia.whereas，after anesthesia induction，the participants in the pecs group receive an ultrasound-guided pecs block and a 15 minute observation time prior before the start of the operation. pecs block technology： a broadband (5-12 hertz) linear array probe of sonosite edge portable ultrasound system (sonosite inc,bethel,washington) is used, with an imaging depth of 4 to 6 cm. after cleaning the infraclavicular and axillary regions with chlorhexidine, the probe is placed below the lateral third of the clavicle, similar to what is done when performing infraclavicular brachial plexus block. after recognition of the appropriate anatomical structures, the skin puncture point is infiltrated with 2% lignocaine, then the block is performed by using a 20-gauge tuohy needle. the needle is advanced to the tissue plane between the pectoralis major and pectoralis minor muscle at the vicinity of the pectoral branch of the acromiothoracic artery, and 10 ml of 0.35% ropivacaine deposited. in a similar manner, 20 ml is deposited at the level of the third rib below the serratus anterior muscle with the intent of spreading injectate to the axilla.

Eligibility criteria:
inclusion criteria: * modified radical mastectomy * american society of anesthesiologists physical status 1-3 * bmi 18-35 kg/m2 exclusion criteria: * declining to give written informed consent； * uncontrolled hypertension； * allergy to local anesthetics； * pregnancy； * alcohol or drug abuse； * prior breast surgery except for diagnostic biopsies； * contraindication to the use of regional anesthesia； * history of chronic pain or psychiatric disorder and pregnant patients； * consumption of nsaid, cyclooxygenase-2 inhibitors or paracetamol within 24 hours before the investigation； * infection at the needle site. * inability to properly describe postoperative pain to investigators (eg, language barrier, neuropsychiatric disorder)

Keywords: breast neoplasms nerve block anesthesia
amplatzer pfo occluder post-marketing surveillance study

Conditions: PFO - Patent Foramen Ovale

Summary: the purpose of the amplatzer pfo occluder post-marketing clinical use surveillance study is to observe the frequency, type and degree of adverse device effects and adverse events in order to assure the safety of the new medical device, and to collect safety and efficacy information for evaluating the results of the clinical use.

based on the ministerial ordinance on good post-marketing study practice for medical device, the surveillance will register patients with patent foramen ovale (pfo) who have experienced a pfo-related cryptogenic cerebral infarction (including diagnosed paradoxical cerebral embolism) or transient ischemic attack (determined by positive head imaging such as dwi) in whom an amplatzer pfo occluder implant was attempted (marketing approval no. 30100bzx00024000, date may 28, 2019, hereinafter referred to as "pfo occluder").

Eligibility criteria:
inclusion criteria: * refer to amplatzer pfo occluder ifu exclusion criteria: * refer to amplatzer pfo occluder ifu
application of 3d printed prosthesis in limb salvage surgery for bone tumors

Conditions: Malignant Tumor

Summary: to report the patients who underwent 3d-printed bone prosthesis replacement in henan cancer hospital in the next 10 years, and collect the postoperative complications and limb function of these patients.

to report the patients who underwent 3d-printed bone prosthesis replacement in henan cancer hospital in the next 10 years. the basic data, treatment methods, postoperative complications and limb function of these patients were collected.

Eligibility criteria:
inclusion criteria: men and women of all ages are welcome. pathologically confirmed in our hospital as a subtype of malignant tumor. he received 3d printed bone prosthesis replacement in our hospital. exclusion criteria: not applicable.
endometrial flora in women undergoing ivf treatments

Conditions: Endometrial Flora Characterization in Infertile Women

Summary: characterization of the female genital tract microbiome in women undergoing ivf treatment

the primary goal with the purpose of our study is to examine the uterine microbiome by next-generation sequencing of the bacteria specific regions . vaginal and uterine swabs will be taken in different women undergoing ivf /pgd. novel bacteria and results of taxonomy assignments will be examine to find correlation of uterine flora with ivf and obstetrical outcomes. the metagenomics approach will be used to seek previously unidentified bacterial species in the human upper genital tract.

Eligibility criteria:
inclusion criteria: * all undergoning ivf treatment * embryo transfer of one blastocyst exclusion criteria: * more then one embryo transfer * recent antibacterial treatment
avis-phageinlyon clinic

Conditions: Bone Infection

Summary: avis-phageinlyon clinic study is a single site non-interventional retrospective and prospective study, initiated by the hospices civils de lyon. population targeted are patients referred to the hospices civils de lyon for a medical advice for a phage therapy from 2015 to 2028. the primary objective is to quantify the phage therapy requests received at the hospices civils de lyon. 1500 patients will be included in the study.


Eligibility criteria:
inclusion criteria: * - patient referred to the hospices civils de lyon for a phage therapy request from 01/01/2015 to 01/01/2028. * avis-phageinlyon clinic study information notice provided to the patient exclusion criteria: * - opposition of trial participant

Keywords: bacteriophage medical advice
pet imaging with [18f]f-arag in advanced non-small cell lung cancer (nsclc)

Conditions: Non-small Cell Lung Cancer (NSCLC)

Summary: this is a prospective, single center, single-arm clinical trial in 20 patients with non-small cell lung cancer (nsclc) undergoing pd-1/pd-l1-directed therapy. this research is being done to find out if the radioactive compound called \[18f\]f-arag is a helpful imaging agent for detecting changes in cancer's anti-tumor immune response (or activation of t-cell) levels for non-small cell lung cancer (nsclc) patients who will receive a cancer immunotherapy regimen (immunotherapy works by encouraging the body's own immune system to attack the cancer cells).

the purpose of this study is to find out how the radiotracer called \[18f\]f-arag can help investigate changes in cancer's anti-tumor immune response (or activation of t-cell) levels during positron emission tomography (pet) scans. \[18f\]f-arag has the potential to serve as a noninvasive imaging biomarker in the monitoring of t-cell mediated anti-tumor immune response following administration of an immunotherapeutic agent. participants in this study will have tests, exams and procedures that are for study purposes. participants will be in this study up to one month which will include about three clinic visits. a baseline \[18f\]f-arag pet-ct will be obtained 0-7 days before a nsclc patient receives pd-1/pd-l1 immunotherapy. a second \[18f\]f-arag pet-ct will be performed 10-14 days after pd-1/pd-l1 immunotherapy is administered.

Eligibility criteria:
inclusion criteria: * age 18 years or older and willing and able to provide informed consent. * subjects with stage i, ii, or iii a nsclc and plan to receive neoadjuvant pd-1/pd-l1 immunotherapy with an intention for curative surgery. subjects will be receiving neoadjuvant immunotherapy through enrollment in therapeutic clinical trials * eastern cooperative oncology group (ecog) performance status of 0, 1, or 2 at the time of enrollment. * for females of childbearing potential, negative serum pregnancy test within a 10 day period will be obtained prior to pet study. exclusion criteria: * severe impaired renal function with estimated glomerular filtration rate \<30 ml/min/1.73 m2 and/or on dialysis. * pregnant female patients; breastfeeding female patients. * any medical condition that in the opinion of the study investigators would constitute a safety risk to the subject. * any investigational radiation exposure in the past calendar year that in combination with the radiation exposure from this study would exceed 5 rem. * administered a radioisotope ≤5 physical half-lives prior to the day of pet/ct.

Keywords: j19119 pet/ct [18f]f-arag nsclc pd-1 pd-l1 immunotherapy
impact of highest drain fluid amylase levels on surgical outcomes and postoperative interventions in patients undergoing pancreaticoduodenectomy

Conditions: Pancreas; Fistula

Summary: this study investigated the impact of highest drain fluid amylase (dfa) level on postoperative pancreatic fistula (popf) severity and outcomes of patients undergoing pancreaticoduodenectomy (pd) with popf. patient demographics of biochemical popf and clinically relevant popf (cr-popf) were compared. predictive factors were assessed using binary logistic regression. receiver operating characteristic curve analysis was performed to determine the optimal cutoff value of highest dfa (beyond 3 days post-pd). the investigators compared length of hospital stay, surgical mortality rates, and need for postoperative interventions by highest dfa level.


Eligibility criteria:
inclusion criteria: * underwent pd from october 2010 to september 2018 in our institution exclusion criteria: * younger than 20 years of age * clinical information was unavailable due to private or legal issues * receiving pd without pancreaticojejunostomy
s-1 and irinotecan in treating patients who are undergoing surgery for locally advanced stomach cancer

Conditions: Gastric Cancer

Summary: rationale: drugs used in chemotherapy, such as s-1 and irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. giving more than one drug (combination chemotherapy) may kill more tumor cells. giving chemotherapy before surgery may shrink the tumor so that it can be completely removed. purpose: this phase ii trial is studying how well giving s-1 together with irinotecan works in treating patients who are undergoing surgery for locally advanced stomach cancer.

objectives: primary * determine the efficacy of neoadjuvant s-1 and irinotecan in patients with locally advanced gastric cancer. secondary * determine the histological response in patients treated with this regimen. * determine the overall survival of patients treated with this regimen. * determine the progression-free survival of patients treated with this regimen. * determine the toxicity of this regimen in these patients. * determine postoperative morbidity in patients treated with this regimen. * determine the rate of potentially curative surgery in patients treated with this regimen. outline: this is a multicenter study. patients receive oral s-1 on days 1-21 and irinotecan iv over 90 minutes on days 1 and 15. treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. patients then undergo gastrectomy with lymphadenectomy. after surgery, patients resume treatment with s-1 alone as before for 1 year. projected accrual: a total of 70 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: * histologically confirmed gastric adenocarcinoma * locally advanced disease * clinical stage t3-4, n0-3, m0 (according to the japanese gastric cancer classification) * planning to undergo curative surgery after neoadjuvant chemotherapy patient characteristics: age * 20 to 75 performance status * ecog 0-1 life expectancy * not specified hematopoietic * wbc 4,000-12,000/mm\^3 * granulocyte count ≥ 2,000/mm\^3 * platelet count ≥ 100,000/mm\^3 * hemoglobin ≥ 9.0 g/dl hepatic * ast and alt ≤ 100 u/l * bilirubin ≤ 1.5 mg/dl renal * creatinine normal or * creatinine clearance ≥ 50 ml/min pulmonary * pao_2 \> 60 mm hg on room air other * able to swallow oral medication prior concurrent therapy: biologic therapy * no prior biologic therapy for gastric cancer chemotherapy * no prior chemotherapy for gastric cancer endocrine therapy * no prior endocrine therapy for gastric cancer radiotherapy * no prior radiotherapy for gastric cancer surgery * no prior surgery for gastric cancer other * no other prior therapy for gastric cancer

Keywords: adenocarcinoma of the stomach stage ii gastric cancer stage iii gastric cancer stage iv gastric cancer
impact of anterior cross bite treatment on children's speech performance

Conditions: Cross Bite; Malocclusion; Speech; Quality of Life

Summary: the goal of this prospective, single-arm clinical trial is to evaluate the speech performance of children with anterior dental crossbite before and after correction. also, to assess the impact of early interceptive orthodontic treatment in the mixed dentition stage to correct the anterior dental crossbite on the quality of life of children. fifty children of both sexes aged from 8 to 10 years were enrolled and evaluated using the study's inclusion \& exclusion criteria. before beginning interceptive orthodontic treatment, each child underwent full mouth treatment. then, using a removable anterior expansion screw along with posterior bite planes to treat the anterior crossbite. all children were subjected to the protocol of speech evaluation before appliance insertion and after complete correction of anterior crossbite. also, the child perceptions questionnaire (cpq 8-10) in the brazilian version was used to gauge how the anterior crossbite affected the children's oral health-related quality of life.


Eligibility criteria:
inclusion criteria: * healthy cooperative children aged 8-10 years * have at least one or more maxillary permanent incisors in a crossbite relationship * fully erupted four first permanent molars * angle class i molar relationship and class i skeletal relationship * the mother language of all the subjects was arabic. exclusion criteria: * children with systemic illness or previous history of speech therapy * children who are ill-habituated or unable to follow up * children with previous orthodontic treatment * uncooperative children * anterior skeletal or functional crossbite * presence of sucking habits

Keywords: crossbite speech expansion screw quality of life
effect of mirror therapy on the arteriovenous fistula cannulation-related pain and anxiety

Conditions: Pain, Chronic; Fistula; Hemodialysis Complication

Summary: pharmacological and non-pharmacological methods are frequently used to reduce cannulation-related pain in patients with fistulas. non-pharmacological approaches have been more favored than pharmacological approaches for some reasons, including ease of use and fewer side effects. patients describe worry about the success of needling and resigned acceptance of pain and anxiety about dialysis needles. with this background in mind, mirror therapy has been introduced as one of the non-pharmacological interventions in the domain of pain management.

patients undergoing hemodialysis experience pain, anxiety and stress due to large-gauge needle punctures necessary to ensure efficient arteriovenous fistula flow. in addition, anxiety disorders are prevalent in hemodialysis patients, primarily caused by invasive procedures and dialysis machine alarm sounds. patients describe worry about the success of needling and resigned acceptance of pain and anxiety about dialysis needles. therefore, when performing an avf puncture, nursing care should prioritise the management of pain and anxiety. with this background in mind, mirror therapy has been introduced as one of the non-pharmacological interventions in the domain of pain management. it has been reported that viewing the picture of a healthy limb could moderate pain perception in the affected one

Eligibility criteria:
inclusion criteria: * patients aged 18 years and older * patients who received hemodialysis (hd) treatment with an arteriovenous fistula (avf) for at least 3 months * patients receiving hd treatment 3 days a week for 4 hours each session * patients with a pain score of ⩾1 during avf cannulation, measured by a visual analog scale (vas) * patients able to communicate in turkish * patients without psychiatric disorders that impair communication * patients who agreed to participate in the study exclusion criteria: * patients who were known to present difficulties with fistula cannulation (requiring multiple cannulations) * patients with a history of hematoma or stenosis in the arteriovenous fistula (avf) * patients with an infection at the fistula site * patients who took painkillers within 3 hours prior to treatment * patients unable to maintain a sitting position on the bed * patients with low vision or visual disturbances (30 cm or less) * patients who did not wish to participate in the study
rapid eating is linked to emotional eating in obese women relieving from bariatric surgery

Conditions: Obesity

Summary: the aim of the study was to analyse eating rate in comparison to other aspects of eating habits in women suffering from severe/massive obesity.

eating rate is associated with bmi and weight gain in various populations and is a factor modulating the risk of complications after bariatric surgery. the aim of the present study is to determine whether common difficulties to change eating rate in subjects with obesity candidate to bariatric surgery could be due to more extensive abnormalities in eating behaviour.

Eligibility criteria:
inclusion criteria : * bmi ≥ 35 kg/m * responses to a self-administered questionnaire distributed between november 2011 and march 2014 to female patients attending a nutrition consultation for overweight, or attending an outpatient visit prior to bariatric surgery, both within the champagne-ardenne specialized obesity clinic, at the university hospital robert debré in reims, france * patients who agree to participate to the study * major patient exclusion criteria : * patient under law protection * minor patient * patients with uncontrolled diabetes (hba1c ≥ 8.0% at inclusion) or those treated with glucagon-like peptide-1 (glp-1) receptor antagonists, as well as patients treated by glucocorticoids (their current treatment was systematically reported)

Keywords: obese food behaviour eating rate
exploration of gcase activity to identify a subpopulation eligible for a therapeutic trial in dementia with lewy bodies

Conditions: Dementia with Lewy Bodies

Summary: this research focuses on the activity of an enzymatic protein: glucocerebrosidase, in dementia with lewy bodies (dlb). indeed, the mutation of the gba gene responsible for a decrease in the activity of glucocerebrosidase is the most frequent known genetic risk factor in dlb. however, mutations of the gba gene are known in another pathology, gaucher disease, in which treatments have been developed. the objective of this research is to determine if glucocerebrosidase activity is decreased in dlb. this hypothesis could open up a therapeutic perspective, with treatments already used in gaucher disease.

population: 118 patients and 118 control subjects act of research: blood test objectifs : * comparison of glucocerebrosidase activity between patients and controls * search for variants or mutations of the gba gene and correlation with glucocerebrosidase activity * correlation between clinical characteristics (updrs motor scale, mmse cognitive scale) and gcase activity in patients * identification of macrophage abnormalities and the impact of treatments targeting the gba pathway on the deregulation of biomarkers in patient macrophages.

Eligibility criteria:
inclusion criteria for patients : * male or female aged ≥ 50 years old * presence of an accompanying person * dementia with lewy bodies according to the revised criteria of mc keith 2017 inclusion criteria for controls: * male or female aged ≥ 50 years old * absence of cognitive impairment and clinical element for a neurodegenerative disease exclusion criteria for patients: * other neurodegenerative disease * gaucher disease exclusion criteria for controls: * neurodegenerative disease * cognitive impairment of all causes

Keywords: glucocerebrosidase gba gene